bavituximab + carboplatin + pemetrexed

Bavituximab + carboplatin + pemetrexed is an investigational combination regimen consisting of three agents: - **Bavituximab** is a chimeric monoclonal antibody that targets phosphatidylserine exposed on the surface of tumor blood vessels and tumor cells. By binding to phosphatidylserine, bavituximab is thought to stimulate an immune-mediated anti-tumor response and disrupt the tumor vasculature. - **Carboplatin** is a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **Pemetrexed** (brand name Alimta) is an antifolate chemotherapy agent that inhibits several folate-dependent enzymes involved in nucleotide synthesis. This combination has been studied primarily for non-small cell lung cancer (NSCLC), particularly non-squamous subtypes. The rationale for combining these agents includes potential synergistic effects between immunotherapy (bavituximab) and cytotoxic chemotherapy (carboplatin and pemetrexed). Bavituximab was developed by Peregrine Pharmaceuticals.